Sawa Ito

Phase 2 Study of Interferon-Gamma and Donor Lymphocyte Infusion for the Treatment of Relapsed Myeloid Malignancies After Allogeneic Stem Cell Transplantation

Food and Drug Administration · R01

Contact PI · $1.7M · University of Pittsburgh at Pittsburgh

Interferon-γ in Combination with Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes After Haploidentical Donor Stem Cell Transplantation

National Cancer Institute · R21

Contact PI · $408.8K · University of Pittsburgh at Pittsburgh

Cancer Center Support Grant

National Cancer Institute · P30

Project lead · $579K · University of Pittsburgh at Pittsburgh

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

Principal investigator · Recruiting · Phase 1

Sawa Ito, MD

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Principal investigator · Recruiting · Phase 2

Sawa Ito, MD

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Principal investigator · Completed · Early phase 1

Sawa Ito, MD

Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids

Principal investigator · Terminated · Phase 1, Phase 2

National Heart, Lung, and Blood Institute (NHLBI)